VasGene - New Therapeutics from Vascular Technology
Site Navigation
EphB4
Ephrin
B2/EphB4 antagonists/Cancer
Blocking this receptor/ligand pair inhibits the end stage of tumor blood vessel formation,
as well as causes direct growth inhibition of certain cancers. VasGene has licensed
technology related to this pathway from California Institute of Technology, and these
compounds have generated promising preclinical results against a variety of cancers.
Ephrin B2/EphB4 antagonists/ Ophthalmology
Ephrin B2/Eph B4 are also involved in growth regulation of new blood vessels in the eye. Utility of
Ephrin antagonists for suppressing neovascularization inherent to the age–related macular degeneration
(AMD), a disease affecting an estimated 1.7 million Americans, opens an entry into ophtalmology market
for Vasgene.
EphB4 monoclonal antibody staining of mammalian cells.
Green EphB4 staining is strongly localized to the plasma membrane, as expected
for detection of a membrane-bound receptor. Nuclei are shown in blue.
EphB4 References
Nakamoto M, Bergemann AD.
Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech. 2002 Oct 1;59(1):58-67. Review.
Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM.
Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer. 2002 Feb 15;94(4):934-9.
Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE.
Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol. 2001;2(1):15. Epub 2001 Dec 21.
Wang HU, Chen ZF, Anderson DJ.
Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998 May 29;93(5):741-53.